AllianceBernstein’s Prime Medicine PRME Stock Holding History

AllianceBernstein’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$523K	Buy	150,300 +27,840	+23%	+$92.5K	﹤0.01%	2681
2026 Q1	$425K	Buy	122,460 +13,770	+13%	+$52.4K	﹤0.01%	2718
2025 Q4	$377K	Hold	108,690	–	–	﹤0.01%	2802
2025 Q3	$602K	Sell	108,690 -58,730	-35%	-$239K	﹤0.01%	2584
2025 Q2	$414K	Buy	167,420 +91,420	+120%	+$141K	﹤0.01%	2751
2025 Q1	$151K	Hold	76,000	–	–	﹤0.01%	2993
2024 Q4	$222K	Hold	76,000	–	–	﹤0.01%	2999
2024 Q3	$294K	Buy	76,000 +5,810	+8%	+$26.9K	﹤0.01%	2927
2024 Q2	$361K	Buy	70,190 +32,240	+85%	+$195K	﹤0.01%	2838
2024 Q1	$266K	Buy	37,950 +590	+2%	+$4.47K	﹤0.01%	2845
2023 Q4	$331K	Buy	37,360 +5,520	+17%	+$42.5K	﹤0.01%	2799
2023 Q3	$304K	Buy	31,840 +5,300	+20%	+$68.8K	﹤0.01%	2801
2023 Q2	$389K	Buy	+26,540	New	+$371K	﹤0.01%	2761

Other funds holding PRME

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

AllianceBernstein's PRME Position: Q2 2026 in Review

AllianceBernstein increased its Prime Medicine (PRME) stake by 23% in Q2 2026, buying an estimated $92.5K and bringing the position to 150,300 shares worth $523K. The position accounts for ﹤0.01% of the portfolio, ranked #2681.

AllianceBernstein first reported a position in PRME in Q2 2023 and has held it in 13 quarters since. The position peaked at $602K in Q3 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

AllianceBernstein held 150,300 shares of Prime Medicine worth $523K as of Q2 2026.
AllianceBernstein bought 27,840 Prime Medicine shares in Q2 2026, an estimated $92.5K.
Prime Medicine made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2681 holding.
AllianceBernstein first reported a position in Prime Medicine in Q2 2023 and has held it in 13 quarters since.
AllianceBernstein's Prime Medicine position peaked at $602K in Q3 2025.
188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.